Emerging Technologies for Heart Diseases
Volume 1: Treatments for Heart Failure and Valvular Disorders
- 1st Edition - August 19, 2020
- Imprint: Academic Press
- Editor: Udi Nussinovitch
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 1 3 7 0 6 - 2
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 3 7 0 7 - 9
The increasing pace of advances in cardiology throughout the last few decades has fundamentally altered the natural course of heart patients. In the last few years, available th… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThe increasing pace of advances in cardiology throughout the last few decades has fundamentally altered the natural course of heart patients. In the last few years, available therapies have been revolutionized completely by new transcatheter therapeutic approaches, novel ventricular assist devices, and new drugs. Also, molecular biology and genetics have a rapidly growing impact on cardiovascular diseases, enabling the field of regenerative medicine to become increasingly closer to routine clinical implementation.
Emerging Technologies for Heart Diseases was conceived to cover the recent extensive literature on current and novel therapeutic options for cardiac patients. The first volume is dedicated to heart failure and valvular disorders, and the second covers myocardial ischemia and arrhythmias. The clinical topic is addressed in several chapters divided according to the therapeutic approach (mechanical or electrical device-based, or cell and gene-based). Each of the 46 chapters focuses on clinically available solutions, new therapies currently under evaluation in clinical trials, promising preclinical technologies, and emerging concepts and innovations that have not yet been tested in a preclinical model. Also, the book discusses future challenges and opportunities for clinical implementation. Lessons learned from abandoned experimental practices are also covered, giving the readers the widest possible perspective of current therapeutic dilemmas.
Overall, this textbook was designed for physicians who want to stay up-to-date with current therapies and those of the future, for biomedical companies, and for those who wish to broaden their knowledge of new cardiovascular therapeutic options.
- Provides a comprehensive review of the latest therapeutic developments for heart failure, valvular disorders, myocardial ischemia and arrhythmias, and their clinical implications
- Written by both specialists in the field and established researchers, it delivers a review of emerging medical technologies and presents insight into their therapeutic promise
- Chapters are arranged according to disease pathogeneses and relevance and include coverage of the mechanical, electrophysiological, and biological approaches for the management of patients with heart failure should be replaced with heart failure and valvular disorders
Biomedical companies and basic scientists who develop biological and device-based approaches for the treatment of heart conditions. Medical professionals who wish to enhance their knowledge of current and emerging medical technologies developed for the treatment of cardiovascular diseases including cardiologists, cardio-thoracic surgeons, internal-medicine specialists. Medical students who are interested in medical advancements will find this book of great interest.
- Cover
- Title page
- Contents
- Copyright
- Dedication
- Contributors
- Preface
- Disclaimer
- Volume 1
- Chapter 1: Keeping a finger on the pulse—a brief history of cardiovascular medicine
- Abstract
- 1.1. Introduction
- 1.2. Discovery of the circulation
- 1.3. The pulse
- 1.4. Physical examination of the chest
- 1.5. Instruments of precision
- 1.6. Cardiac imaging
- 1.7. Electrocardiography
- 1.8. Cardiac physiology
- 1.9. Hypertension
- 1.10. Ischemic heart disease
- 1.11. Early cardiac surgery
- 1.12. Cardiac catheterization
- 1.13. Selective coronary angiography
- 1.14. Interventional cardiology
- 1.15. Advanced cardiac surgery
- 1.16. Management of arrhythmias
- 1.17. Measurement of cardiac function
- 1.18. Artificial valves and heart transplants
- 1.19. Conclusions
- Section I: Treatment of heart failure – device-based therapies
- Chapter 2: Artificial mechanical hearts and ventricular assist devices
- Abstract
- 2.1. Introduction
- 2.2. Clinically available solutions
- 2.3. Clinical trials and experimental treatments
- 2.4. Preclinical technologies
- 2.5. Conclusions, future challenges and opportunities
- Chapter 3: Percutaneous left and right ventricular support devices
- Abstract
- 3.1. Introduction
- 3.2. Clinically available solutions
- 3.3. Clinical trials and experimental data
- 3.4. Preclinical technologies
- 3.5. Conclusions, future challenges and opportunities
- Chapter 4: Cardiac resynchronization therapy and device-based cardiac contractility modulation
- Abstract
- 4.1. Introduction
- 4.2. Cardiac resynchronization therapy
- 4.3. Clinically available solutions
- 4.4. Clinical trials and experimental treatments
- 4.5. Emerging concepts and innovations
- 4.6. Cardiac contractility modulation
- 4.7. Conclusions, future challenges and opportunities
- Chapter 5: Left atrial decompression devices
- Abstract
- 5.1. Introduction
- 5.2. Clinically available solutions
- 5.3. Clinical trials and experimental treatments
- 5.4. Preclinical technologies
- 5.5. Emerging concepts and innovations
- 5.6. Conclusions, future challenges and opportunities
- Chapter 6: Novel treatments for diastolic heart failure
- Abstract
- 6.1. Introduction
- 6.2. Clinically established solutions and abandoned medical approaches
- 6.3. Clinical trials and experimental treatments
- 6.4. Preclinical technologies
- 6.5. Emerging concepts and innovations
- 6.6. Conclusions, future challenges and opportunities
- Disclosures
- Chapter 7: Ultrafiltration and other treatments of volume overload in congestive heart failure
- Abstract
- 7.1. Introduction
- 7.2. Conventional management of heart failure
- 7.3. Extracorporeal ultrafiltration therapy—clinical considerations
- 7.4. Impact of ultrafiltration therapy on cardiopulmonary function
- 7.5. Impact on renal function
- 7.6. Ultrafiltration fluid removal target
- 7.7. Monitoring of ultrafiltration
- 7.8. The durability of beneficial effects
- 7.9. Clinical trials
- 7.10. Practical aspects and current guidelines
- 7.11. Peritoneal dialysis for chronic heart failure
- 7.12. Emerging technologies
- 7.13. Conclusions, future challenges and opportunities
- Chapter 8: Cardiac physical remodeling and percutaneous solutions for the treatment of advanced heart failure
- Abstract
- 8.1. Introduction
- 8.2. Less invasive clinically available solutions
- 8.3. Ventricular restraint therapy
- 8.4. The transcatheter renal venous decongestion (TRVD) concept
- 8.5. Neuromodulators
- 8.6. Conclusions, future challenges and opportunities
- Section 2: Treatment of systolic heart failure - cell and gene based therapies, tissue engineering and biopolymers
- Chapter 9: Cardiac xenotransplantation
- Abstract
- 9.1. Introduction
- 9.2. Pathobiological barriers in cardiac xenotransplantation
- 9.3. Current progress in cardiac xenotransplantation
- 9.4. Progress toward the clinic
- 9.5. Emerging concepts and innovations
- 9.6. Future challenges and opportunities
- 9.7. Conclusions
- Acknowledgments
- 9.8. Conflict of interest
- Chapter 10: Marrow-derived stromal cells for cardiac regeneration
- Abstract
- 10.1. Introduction
- 10.2. Preclinical technologies
- 10.3. Clinical trials of bone marrow-derived stromal cells
- 10.4. Emerging concepts and innovations for using bone marrow- derived mesenchymal stem/stromal cells for cardiac repair
- 10.5. Future Conclusions, future challenges and opportunities
- Chapter 11: Heart-derived cells for therapeutics
- Abstract
- 11.1. Introduction: the emergence of cardiac-derived cell therapies
- 11.2. Mechanism(s) and methodology underlying cardiosphere-derived cells culture
- 11.3. Preclinical data supporting cardiosphere-derived cells-mediated repair of injured myocardium
- 11.4. Clinical trial experience
- 11.5. Mechanisms underpinning therapeutic regeneration by cardiosphere-derived cells
- 11.6. Emerging concepts and innovations
- 11.7. Conclusions, future challenges and opportunities
- Acknowledgment
- Chapter 12: Human pluripotent stem cells for cardiac regeneration
- Abstract
- 12.1. Introduction
- 12.2. Hurdles of clinical translation
- 12.3. Preclinical translation
- 12.4. Clinical translation
- Acknowledgment
- Chapter 13: Heart regeneration using somatic cells
- Abstract
- 13.1. Introduction
- 13.2. Cellular reprogramming
- 13.3. The role of the microenvironment in shaping cardiac reprogramming
- 13.4. Human direct cardiac reprogramming
- 13.5. Cell therapy and bioengineering
- 13.6. Conclusions and future directions
- Chapter 14: Tissue engineered heart repair
- Abstract
- 14.1. Introduction
- 14.2. Heart muscle tissue engineering: methodological considerations
- 14.3. Heart muscle tissue engineering: surgical considerations
- 14.4. Heart muscle tissue engineering: immunological considerations
- 14.5. Conclusions
- Acknowledgments
- Chapter 15: Decellularization of whole hearts for cardiac regeneration
- Abstract
- 15.1. Introduction
- 15.2. Procedures before whole-heart decellularization
- 15.3. Procedures during whole-heart decellularization
- 15.4. Procedures after whole-heart decellularization
- 15.5. Conclusions, future challenges and opportunities
- Chapter 16: Gene and protein-based therapies for improving cardiac performance and regeneration
- Abstract
- 16.1. Enhancement of cardiac function in heart failure – Gene therapy approach and protein-based therapy
- 16.2. Improvement of right ventricular function in pulmonary hypertension—gene therapy and protein-based approaches
- 16.3. Cardiac regeneration: Gene therapy approach and protein-based therapy
- 16.4. Conclusions
- Acknowledgments
- Chapter 17: Injectable biopolymers in the treatment of heart failure and cardiac remodeling
- Abstract
- 17.1. Introduction
- 17.2. Clinical solutions
- 17.3. Clinical trials and experimental treatments
- 17.4. Emerging preclinical technologies and concepts for biopolymer therapies
- 17.5. Conclusions, future challenges and opportunities
- Acknowledgments
- Section 3: Treatment of systolic heart failure - novel pharmacological treatments
- Chapter 18: Novel pharmacotherapies for heart failure
- Abstract
- 18.1. Introduction
- 18.2. HFrEF: pathophysiology and current drug targets
- 18.3. HFpEF: pathophysiology and current drug targets
- 18.4. Clinically available solutions–recent advances
- 18.5. Clinical trials and experimental treatments
- 18.6. Preclinical therapies for potential consideration in HF
- 18.7. Conclusions, future challenges and opportunities
- Section 4: Treatment of valvular disorders
- Chapter 19: Heart valve tissue engineering: current preclinical and clinical approaches
- Abstract
- 19.1. Introduction
- 19.2. Clinical experience with tissue engineered heart valves
- 19.3. Preclinical studies in heart valve tissue engineering
- 19.4. Conclusions, future challenges and opportunities
- Chapter 20: Transcatheter aortic valve replacement
- Abstract
- 20.1. Introduction
- 20.2. TAVR technology
- 20.3. Clinical trials and experimental treatments
- 20.4. TAVR data
- 20.5. Current issues
- 20.6. Conclusions, future challenges and opportunities
- Chapter 21: Transcatheter mitral valve therapies for degenerative and functional mitral regurgitation
- Abstract
- 21.1. Introduction
- 21.2. Leaflet repair
- 21.3. Annuloplasty
- 21.4. Chordal repair
- 21.5. Ventricular remodeling devices
- 21.6. Conclusions
- Chapter 22: Transcatheter mitral valve replacement
- Abstract
- 22.1. Introduction
- 22.2. Clinical trials and experimental treatments
- 22.3. Preclinical technologies
- 22.4. Emerging concepts and innovations
- 22.5. Future challenges and opportunities
- 22.6. Conclusions
- Chapter 23: Transcatheter treatments for tricuspid valve diseases
- Abstract
- 23.1. Introduction
- 23.2. Clinically available solutions
- 23.3. Clinical trials and experimental treatments
- 23.4. Preclinical technologies (Fig. 23.7)
- 23.5. Future challenges and opportunities
- 23.6. Conclusions
- Index
- Edition: 1
- Published: August 19, 2020
- No. of pages (Hardback): 553
- No. of pages (eBook): 553
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780128137062
- eBook ISBN: 9780128137079
UN
Udi Nussinovitch
Udi Nussinovitch, MD, PhD graduated from the Sackler Faculty of Medicine, Tel Aviv University, training at the Sheba Medical Center, Rambam Healthcare Center and Meir Medical Center, while concurrently graduating with a PhD in cardiac electrophysiology from the Technion Institute of Technology, Israel.
Dr Nussinovitch has dedicated his research to investigating novel therapeutic approaches for cardiac disorders and the modulation of the cardiac electrophysiologic substrate for therapeutic purposes. He serves as director of the Applicative Cardiovascular Research Center (ACRC), affiliated to Tel Aviv University.
Dr Nussinovitch founded several biotech companies, and has been the recipient of several research awards. He carries out his clinical work at the Meir Medical Center, a medical facility and leading referral center in Israel.
Affiliations and expertise
Applicative Cardiovascular Research Center (ACRC) and Department of Cardiology, Meir Medical Center, affiliated to Tel Aviv University, IsraelRead Emerging Technologies for Heart Diseases on ScienceDirect